Covera Health reaches nearly 6 million covered lives: radiology quality control becomes a product for insurers

By Pulse 2.0 · November 3, 2026.

Covera Health, a platform that combines artificial intelligence with radiologist oversight to measure quality and diagnostic accuracy in radiology, has named Jeremy Livianu Chief Legal Officer and Adam Travis, a board-certified radiologist, General Manager of Imaging Strategy and Growth. Travis joins on November 17, 2026.

The appointments follow a period of expansion. According to the company's own figures, Covera serves nearly 6 million covered lives across more than 6,500 imaging centers. Its clients include five Fortune 50 companies and three of the country's five largest health plans. In 2026, the number of large self-insured employers using the platform reportedly more than doubled, and covered lives in those accounts grew by more than 50%.

The company adds that its AI-powered early detection program reviewed nearly 2 million medical imaging studies over the past year, and that its programs have shown reductions in downstream healthcare costs of up to 12%. These figures were reported by Covera, with no independent validation in the available material, and the “up to” 12% is a ceiling, not an average.

Travis, who previously worked at Teladoc Health, Livongo, Clarify Health Solutions, Boston Consulting Group and RA Capital Management's Raven platform, will lead the expansion of the national imaging provider network. Livianu, with more than twenty years in healthcare and life sciences (Homeward, UpHealth, Cutera, Establishment Labs, Nevro), will oversee corporate governance, regulatory compliance and commercial contracts. The stated goal is to grow from about 6 million lives to 25 million or more.

**Our take.** The most interesting point is not the AI, but who it is being sold to. Covera doesn't sell an image reader to hospitals: it sells employers and insurers a way to see and reward diagnostic quality, something that until now was opaque to those who pay. Its CEO, Ron Vianu, frames it this way: there is a shortage of radiologists, imaging volume grows every year and quality varies in ways payers cannot see. It is a reasonable argument, and the underlying problem is real: if the first study is wrong, all subsequent treatment is built on an error.

The important nuance is that value is shifting from algorithmic accuracy to verification and traceability. This fits a broader trend: in general, regulatory frameworks for clinical AI leave the decision to the physician and spread liability among vendor, institution and clinician. A platform that audits and scores radiologists therefore needs serious legal backing, and hiring a chief legal officer is no coincidence: managing that risk well is part of the product.

Caution is also warranted. A business model that pays or steers patients toward “high-quality” providers based on its own metric raises legitimate questions: how that quality is defined, who audits it and what happens to the lowest-scoring centers. Without published methods or external validation, the “up to 12%” savings and the 2 million studies are indicators of commercial traction, not of proven clinical effectiveness.

In the short term, pressure on radiology will continue: more imaging, fewer specialists and payers who want outcome data. In the long term, this measurement layer could be one piece of a healthcare system with earlier, more consistent diagnoses, one of the concrete ways AI brings us closer to diseases caught in time and, one day, eradicated. But that horizon depends on quality being measured transparently, not just on it selling well.